中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
5期
528-530
,共3页
宋文辉%白志杰%姚世杰%刘谦%王海峰%马庆彤%杨世强%马洪顺
宋文輝%白誌傑%姚世傑%劉謙%王海峰%馬慶彤%楊世彊%馬洪順
송문휘%백지걸%요세걸%류겸%왕해봉%마경동%양세강%마홍순
肾移植%尿路上皮癌%根治性手术
腎移植%尿路上皮癌%根治性手術
신이식%뇨로상피암%근치성수술
Kidney transplantation%Urothelial tumor%Radical operation
目的 总结肾移植术后受者并发自体尿路上皮肿瘤的诊治体会及原因分析.方法 回顾性分析了 2006年1月至2011年7月肾移植术后接受至少6个月的免疫抑制治疗受者的病历资料.结果 在1042例肾移植受者中,发生尿路上皮癌者为11例,发生率为1.06%,全部病例资料完整,其中9例(81.8%)因血尿就诊,2例(18.2%)因查体发现.其中6例为多器官尿路上皮癌.所有患者均经手术治疗,术后辅以化疗或者放疗.其后随访发现8例生存良好,3例死亡.结论 对肾移植后并发血尿症状的患者要高度重视,密切随访,重视术后检查,要高度警惕尿路上皮癌的可能,早期诊断,重视尿道重建造影和输尿管镜检查的作用,积极行根治性手术治疗,减少免疫抑制剂的用量.
目的 總結腎移植術後受者併髮自體尿路上皮腫瘤的診治體會及原因分析.方法 迴顧性分析瞭 2006年1月至2011年7月腎移植術後接受至少6箇月的免疫抑製治療受者的病歷資料.結果 在1042例腎移植受者中,髮生尿路上皮癌者為11例,髮生率為1.06%,全部病例資料完整,其中9例(81.8%)因血尿就診,2例(18.2%)因查體髮現.其中6例為多器官尿路上皮癌.所有患者均經手術治療,術後輔以化療或者放療.其後隨訪髮現8例生存良好,3例死亡.結論 對腎移植後併髮血尿癥狀的患者要高度重視,密切隨訪,重視術後檢查,要高度警惕尿路上皮癌的可能,早期診斷,重視尿道重建造影和輸尿管鏡檢查的作用,積極行根治性手術治療,減少免疫抑製劑的用量.
목적 총결신이식술후수자병발자체뇨로상피종류적진치체회급원인분석.방법 회고성분석료 2006년1월지2011년7월신이식술후접수지소6개월적면역억제치료수자적병력자료.결과 재1042례신이식수자중,발생뇨로상피암자위11례,발생솔위1.06%,전부병례자료완정,기중9례(81.8%)인혈뇨취진,2례(18.2%)인사체발현.기중6례위다기관뇨로상피암.소유환자균경수술치료,술후보이화료혹자방료.기후수방발현8례생존량호,3례사망.결론 대신이식후병발혈뇨증상적환자요고도중시,밀절수방,중시술후검사,요고도경척뇨로상피암적가능,조기진단,중시뇨도중건조영화수뇨관경검사적작용,적겁행근치성수술치료,감소면역억제제적용량.
Objective To analyze the incidence and clinical features of urothelial tumors in renal allograft recipients.Methods A retrospective analysis of 1042 patients received renal allografts who had taken immunosuppression for at least six months between 2006 and 2011 in The First Centre Hospital of Tianjin was performed.Results Eleven cases of uroepithelial tumors were diagnosed in the 1042 cases of renal transplantation ( 1.06% ),of whom 9 cases were noticed by hematuria ( 81.8 % ),2 cases ( 18.2% ) by medical examination.Six patients were diagnosed with multifocal urothelial carcinomas.Surgery was performed on all the patients with renal tumors and followed by chemotherapy or radiotherapy.Conclusion Malignancies in urinary tract after renal transplantation should be bore in mind.Early diagnosis is very important.The treatment options include reducing immunosuppressive agents and removing tumor lesions completely.